These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 10901153)

  • 1. The need for new and better antidepressants: reboxetine a new option.
    Dencker SJ
    Acta Psychiatr Scand Suppl; 2000; 402():6-11. PubMed ID: 10901153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Reboxetine (Edronax)].
    Souery D; Sternon J
    Rev Med Brux; 1999 Dec; 20(6):511-6. PubMed ID: 10672775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reboxetine: the first selective noradrenaline re-uptake inhibitor.
    Kasper S; el Giamal N; Hilger E
    Expert Opin Pharmacother; 2000 May; 1(4):771-82. PubMed ID: 11249515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is there a role for a pure noradrenergic drug in the treatment of depression?
    Montgomery SA
    Eur Neuropsychopharmacol; 1997 Apr; 7 Suppl 1():S3-9; discussion S71-3. PubMed ID: 9169305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of noradrenaline and selective noradrenaline reuptake inhibition in depression.
    Brunello N; Mendlewicz J; Kasper S; Leonard B; Montgomery S; Nelson J; Paykel E; Versiani M; Racagni G
    Eur Neuropsychopharmacol; 2002 Oct; 12(5):461-75. PubMed ID: 12208564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reboxetine: a selective norepinephrine reuptake inhibitor for the treatment of depression.
    Scates AC; Doraiswamy PM
    Ann Pharmacother; 2000 Nov; 34(11):1302-12. PubMed ID: 11098346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reboxetine--another new antidepressant.
    Drug Ther Bull; 1998 Nov; 36(11):86-8. PubMed ID: 10562766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Noradrenaline-selective versus serotonin-selective antidepressant therapy: differential effects on social functioning.
    Dubini A; Bosc M; Polin V
    J Psychopharmacol; 1997; 11(4 Suppl):S17-23. PubMed ID: 9438229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Noradrenaline and serotonin reuptake inhibition as clinical principles: a review of antidepressant efficacy.
    Humble M
    Acta Psychiatr Scand Suppl; 2000; 402():28-36. PubMed ID: 10901156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of the selective noradrenergic reuptake inhibitor reboxetine on the firing activity of noradrenaline and serotonin neurons.
    Szabo ST; Blier P
    Eur J Neurosci; 2001 Jun; 13(11):2077-87. PubMed ID: 11422448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The selective norepinephrine reuptake inhibitor antidepressant reboxetine: pharmacological and clinical profile.
    Hajós M; Fleishaker JC; Filipiak-Reisner JK; Brown MT; Wong EH
    CNS Drug Rev; 2004; 10(1):23-44. PubMed ID: 14978512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor.
    Wong EH; Sonders MS; Amara SG; Tinholt PM; Piercey MF; Hoffmann WP; Hyslop DK; Franklin S; Porsolt RD; Bonsignori A; Carfagna N; McArthur RA
    Biol Psychiatry; 2000 May; 47(9):818-29. PubMed ID: 10812041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the effectiveness of reboxetine versus fluoxetine in patients with atypical depression: a single-blind, randomized clinical trial.
    Taner E; Demir EY; Cosar B
    Adv Ther; 2006; 23(6):974-87. PubMed ID: 17276965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting response: noradrenaline reuptake inhibition.
    Montgomery SA
    Int Clin Psychopharmacol; 1999 May; 14 Suppl 1():S21-6. PubMed ID: 10468325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Noradrenaline in basic models of depression.
    Leonard BE
    Eur Neuropsychopharmacol; 1997 Apr; 7 Suppl 1():S11-6; discussion S71-3. PubMed ID: 9169306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reboxetine, a new noradrenaline selective antidepressant, is at least as effective as fluoxetine in the treatment of depression.
    Andreoli V; Caillard V; Deo RS; Rybakowski JK; Versiani M
    J Clin Psychopharmacol; 2002 Aug; 22(4):393-9. PubMed ID: 12172339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reboxetine: additional benefits to the depressed patient.
    Montgomery SA
    J Psychopharmacol; 1997; 11(4 Suppl):S9-15. PubMed ID: 9438228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reboxetine versus fluoxetine: an overview of efficacy and tolerability.
    Massana J
    J Clin Psychiatry; 1998; 59 Suppl 14():8-10. PubMed ID: 9818624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nicotine, but not mecamylamine, enhances antidepressant-like effects of citalopram and reboxetine in the mouse forced swim and tail suspension tests.
    Andreasen JT; Redrobe JP
    Behav Brain Res; 2009 Jan; 197(1):150-6. PubMed ID: 18786574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. From symptoms to social functioning: differential effects of antidepressant therapy.
    Kasper S
    Int Clin Psychopharmacol; 1999 May; 14 Suppl 1():S27-31. PubMed ID: 10468326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.